Almac was engaged by a virtual, US based Pharmaceutical client seeking EU commercial product approval for their first commercial product – an ultra-orphan, solid oral dose presentation. This EU launch project required designing both the primary and secondary packaging formats (blister / wallet) and origination of country-specific artwork to comply with individual EU market requirements.